Sharechat Logo

Seeka sells out of Zespri after opposing changes to constitution tying shares to trays

Wednesday 4th April 2018

Text too small?

Seeka, New Zealand's biggest kiwifruit grower, has sold out of Zespri Group after opposing constitutional changes at the monopoly export body that tie shareholdings to trays of fruit produced.

The changes were approved by more than 75 percent of shareholders last month but among the resolutions was that shareholders who voted all their shares against the overhaul could require Zespri to buy back their shares.

Holders of 1.78 million shares - or about 1.5 percent of shares on issue - exercised their minority buy-out rights and will receive $8.25 per share, which is within an $8-to-$9 a share valuation range provided by Cameron Partners. The price amounts to a 9.3 percent premium to Zespri's last trading price on the Unlisted platform of $7.55.

Seeka said it will receive about $6.11 million selling about 740,606 shares back to Zespri. Chief executive Michael Franks said the money would be used to repay debt and for working capital.

"We didn't support them but the vote was passed," Franks said. "It's about our return - we're paying back our debt."

The buyback price is just above the carrying value of $8.22 a share in Seeka's accounts as at Dec. 31.

On March 14, shareholders of Zespri voted on a series of resolutions that will impose a cap on the number of shares they can hold relative to trays of kiwifruit produced. It will also phase out dividends for non-producing shareholders over seven years. Existing growers who stop producing after the vote would cease getting dividends after three years

The vote comes after shareholders in 2015 approved plans to strengthen grower control amid concerns about an increasing misalignment between producers and shareholders. The changes required an amendment to the Kiwifruit Export Regulations last year.

Of Zespri's 120.7 million shares on issue, some 18.1 million are held by people no longer connected with the kiwifruit industry and a further 29 percent are held by producers at a ratio of below one share per tray, which Zespri deems "under-shared". At the other end of the spectrum, 8 percent of the shares are held by producers at a ratio of more than four shares per tray, known as "over-shared".

Zespri wants to aim for a ratio of one share for one tray produced but the new cap would set the limit at four shares per tray. A spokeswoman said while one share per tray was seen as ideal, Zespri recognised that it wasn't practical and would make the market in the shares less liquid. Apart from the cap, there was no compulsion for suppliers to hold shares. 

In calendar 2017, Seeka produced 25.5 million gross packed trays of kiwifruit in New Zealand, down from 32 million trays a year earlier.

Seeka shares last traded at $6.30 on the NZX and have gained about 18 percent in the past 12 months, outpacing a 16 percent gain in the S&P/NZX 50 Index.

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares gain as upcoming Fed meeting bolsters yield stocks; Sky TV gains
ESW reaches 90% of SLI Systems, moves to compulsory acquisition
NZ higher against USD as markets await the US Federal Reserve
Hawke's Bay council advances Napier Port IPO plan
Government outlines planned hikes in minimum wage
Chorus could lift its dividend post-UFB rollout but risks remain
T&G Global profit dented by cheaper tomatoes, small grape harvest
NZ posts widest current account deficit since 2009, in line with expectations
Heartland says new bank capital rules won't hurt as much as the market thinks
ISS supports Vital Healthcare's rebel investors

IRG See IRG research reports